New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. - Wikidata - awgldk - TriplyDB

New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.

New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.

http://www.wikidata.org/entity/Q36603335

about

The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells Prostate cancer stem cells: the role of androgen and estrogen receptors Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway.Early human prostate adenocarcinomas harbor androgen-independent cancer cells The androgen receptor plays a suppressive role in epithelial- mesenchymal transition of human prostate cancer stem progenitor cells TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals.Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis.Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals.Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer.Loss of androgen receptor promotes adipogenesis but suppresses osteogenesis in bone marrow stromal cells.Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro.Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma.Androgen receptor increases CD133 expression and progenitor-like population that associate with cisplatin resistance in endometrial cancer cell line.Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.Androgen receptor roles in the development of benign prostate hyperplasia The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Concise review: androgen receptor differential roles in stem/progenitor cells including prostate, embryonic, stromal, and hematopoietic lineages.PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.Leading causes of castration-resistant prostate cancer.Non-coding RNAs in Prostate Cancer: From Discovery to Clinical Applications.Prostate cancer stem cells: from theory to practice.Cancer stem cells in prostate cancer.Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling.Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture.miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer.Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling.Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid.Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.Androgen receptor/let-7a signaling regulates breast tumor-initiating cells.

P2860

Q26765892-9127D03A-D14A-4B65-A493-46D234D44690 Q26778415-8A2F2CBE-B8EE-4CB9-9952-292BD176B404 Q26822406-308B20E4-E1B6-496F-919D-427C5972252A Q33827484-D73D136A-1B9E-4AD5-9CBB-6ED87AA7F5F1 Q35005020-BA71A48F-EE25-4B00-B5CB-19F0D244D200 Q35604311-8AA3CDEC-ADA5-4DF2-96C3-03E9C02264D1 Q36021034-62E32B90-0E94-4F6B-8AFC-01AB6CF8ADC0 Q36298863-684043A1-2398-40BA-ADB8-4A2447E40EA2 Q36407872-E345D1F5-6A17-4379-B480-B297F221682A Q36413827-7A894A5F-D14F-471F-96A1-484D83FDA225 Q36439816-BE1CE169-FA36-40DC-AAA9-CD975E111141 Q36439839-B14CDDF2-B789-431E-B1AD-CA8B10254359 Q36746688-B15ACA53-55BA-4841-8BBA-9C20ABEE3FF3 Q36916291-5CBB0935-B441-49F6-A1A2-21793B1E8665 Q37108694-92A636C3-3FD1-4BD1-8F25-A95750580B56 Q37236912-70939FA6-8460-440C-8FE1-0C737A310884 Q37372163-976A36AC-6E6F-4D6E-AEE6-7424E85C109E Q37392841-42056D88-EC01-4C83-A734-8FD4BF748482 Q37606208-E54D3763-1858-4611-9612-3A55988C9B90 Q37610799-43EF5431-99C9-4193-939A-FCF2871A6730 Q38097574-0E342463-6D6F-4102-AA27-54CD01CC7920 Q38203779-D5C611A4-6618-4AE2-9F5A-943C2C7D9E55 Q38205189-6735D26A-CFEF-48F9-A27D-229B1DDABC65 Q38265574-0C01DADB-85A9-4015-ACA3-F2EC57BFFD96 Q38341864-9FA59CA1-233A-4891-A7DA-4FD0BE37FD7A Q38667234-B1D5A72F-2991-4611-B768-A1836BAFABFD Q38668605-C7E86967-4E60-444F-9746-86BD89D7369C Q38713728-0BE841D8-2BBA-476A-B458-6FE86C0E0A7F Q38731643-3C2552A6-2C68-499D-A687-6A059ED43826 Q38743727-4EC3A77F-7668-4C96-9533-F54B2487C7D1 Q38748082-262041FD-BBB9-4BDD-B34C-7D7326D6EE5B Q38875539-9EE83EB6-3857-4C8E-9BCB-67310CBA2699 Q38884397-5D99DD12-B767-4436-879C-C4DF62B8AD58 Q39121144-7FEC0BB7-C755-44DD-B6DA-E8531CE33FCF Q39136417-545A56F7-19FE-4A75-B42D-803CA0A99ACA Q39143940-56FC999D-EC66-4529-B50A-52F730A68B77 Q46416599-3F6267E9-67AF-4CDC-8F5E-526EF218347F Q48251370-07AE960A-8A40-452F-8616-30F6B7447CD0 Q49283874-B7604485-689F-47FB-9F28-D72D245D2F2F

P2860

New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.

http://www.wikidata.org/entity/Q36603335

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

New therapy targeting differen ...... vs. non-stem/progenitor cells.

@ast

New therapy targeting differen ...... vs. non-stem/progenitor cells.

@en

type

label

New therapy targeting differen ...... vs. non-stem/progenitor cells.

@ast

New therapy targeting differen ...... vs. non-stem/progenitor cells.

@en

prefLabel

New therapy targeting differen ...... vs. non-stem/progenitor cells.

@ast

New therapy targeting differen ...... vs. non-stem/progenitor cells.

@en

P1433

Q36603335-EE85F887-894A-4141-A085-38AB9550B539

P1476

Q36603335-78A1172D-28CD-4729-B6EE-A567C5D1F40D

P2093

Q36603335-0F84281C-7B9D-4BF7-B356-B96A05C1B418

Q36603335-1CAD8F67-D89E-43D0-9FBC-EB4E513951D3

Q36603335-1FB67DF5-B937-4B60-B4F6-3F09692B1792

Q36603335-20B970B2-D943-4664-9A4D-4758433E63BA

Q36603335-3AEA9E49-22B7-4A92-8722-69F9400DAC81

Q36603335-3B7FB9C2-204A-471C-9F5E-1154B5C561A5

Q36603335-4659CAB0-5DB5-4117-9B3F-3593705B40AC

Q36603335-578F0A4C-E782-4FA8-AEAA-2469C6D90933

Q36603335-BBB783A6-B41F-404B-94F0-36719CAB1BF0

Q36603335-BCD618D4-FC51-4663-B151-6EA4700E47BA

P2860

Q36603335-05F39E95-E5D8-4691-95DC-2BC3CE606AF1

Q36603335-06420B17-327A-438E-8E3D-8CCCF38F489F

Q36603335-08E385C8-4DB5-42EF-96C8-5A8C5F2A14C4

Q36603335-12B0BFCF-D39D-4CD9-A4C7-5933B5A7BB90

Q36603335-12BB90CA-C698-49CC-B45D-0AC64DC99CBB

Q36603335-15446A7A-1064-4BD7-BE31-59A18AF10B64

Q36603335-163115A3-E42B-4A9E-AF5A-DEB0843A7896

Q36603335-165F8A35-A795-49C2-94BF-3CDBA7182306

Q36603335-1BBF0064-4F49-479C-ADC9-1D10C7DAE01F

Q36603335-1E56B953-99F0-4403-9719-4F10498B8A81

P304

Q36603335-7A233CDB-63EE-421E-919D-A18185CB9546

P31

Q36603335-E23CB490-A7FA-46BA-88EA-D85B3329A9A3

P356

Q36603335-F875DF08-222F-48FA-99EE-832BD9C23051

P433

Q36603335-CA71D53C-9F32-4A45-B199-DC6628AF1612

P478

Q36603335-96FD405D-DF6F-44CB-8A1B-8B41B6B52953

P50

Q36603335-587B7D15-62FC-46B0-B70E-1560B132DDF5

P577

Q36603335-2F8EBF79-5C2E-4961-837E-73C2B6AC65F7

P5875

Q36603335-2C7B3049-7F5B-4205-87CB-E258BA90B2E7

P698

Q36603335-D03601A5-A766-40CF-AE7F-518693DC0C9E

P932

Q36603335-771CFEC6-C1F9-476A-8803-3305AA98BC68

P356

P1433

Journal of molecular cell biology

P1476

New therapy targeting differen ...... vs. non-stem/progenitor cells

@en

P2093

Chawnshang Chang

http://www.w3.org/2001/XMLSchema#string

Chiuan-Ren Yeh

http://www.w3.org/2001/XMLSchema#string

Chiung-Kuei Huang

http://www.w3.org/2001/XMLSchema#string

Jie Luo

http://www.w3.org/2001/XMLSchema#string

Jing Tian

http://www.w3.org/2001/XMLSchema#string

Kuo-Pao Lai

http://www.w3.org/2001/XMLSchema#string

Lei Li

http://www.w3.org/2001/XMLSchema#string

Liang Liang

http://www.w3.org/2001/XMLSchema#string

Qi Jiang

http://www.w3.org/2001/XMLSchema#string

Shinichi Yamashita

http://www.w3.org/2001/XMLSchema#string

P2860

Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

Prostate cancer stem cells: a new target for therapy

Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo

Genomic profiling of tumor initiating prostatospheres.

The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis

Increased CK5/CK8-positive intermediate cells with stromal smooth muscle cell atrophy in the mice lacking prostate epithelial androgen receptor

Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression

P304

14-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JMCB/MJS042

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230567328

http://www.w3.org/2001/XMLSchema#string

P698

22831834

http://www.w3.org/2001/XMLSchema#string

P932

3570051

http://www.w3.org/2001/XMLSchema#string